HEPA (Hepion Pharmaceuticals, Inc.) Short-Term Debt to Capital

Hepion Pharmaceuticals is establishing a leading scientific and technological center in hepatology, integrating artificial intelligence with the search for anti-fibrotic molecules. This chart of the short-term debt-to-equity ratio reflects 0.00. This metric correlates with the clinical trial stage of current NASH medications, while the stability of the financial framework is maintained through strict limits on testing expenditures and robust patent protection.

This indicator assesses the degree of the company's dependence on short-term debt relative to equity, where changes in the ratio of short-term loans to capital reflect liquidity risk when calculating liabilities against the asset base, which is critical for Hepion Pharmaceuticals (HEPA) due to high financial pressure caused by delegating clinical trials to external contractors as part of its outsourcing strategy.